Target type: biologicalprocess
The chemical reactions and pathways resulting in the formation of 10-formyltetrahydrofolate, the formylated derivative of tetrahydrofolate. [GOC:ai]
The 10-formyltetrahydrofolate (10-formylTHF) biosynthetic process is a crucial metabolic pathway that generates the essential cofactor 10-formylTHF. This cofactor plays a vital role in various cellular processes, including purine biosynthesis, DNA replication, and amino acid metabolism.
The biosynthesis of 10-formylTHF begins with the conversion of tetrahydrofolate (THF) to 5,10-methylenetetrahydrofolate (5,10-methyleneTHF) by the enzyme tetrahydrofolate reductase (THF reductase). 5,10-methyleneTHF is then oxidized to 10-formylTHF by the enzyme 10-formyltetrahydrofolate dehydrogenase. This reaction is coupled to the reduction of NADP+ to NADPH.
The 10-formylTHF biosynthetic pathway is essential for the synthesis of purines. 10-formylTHF serves as a one-carbon donor in the synthesis of purines. It is also required for the biosynthesis of thymidylate, a key component of DNA.
The 10-formylTHF biosynthetic pathway is tightly regulated to ensure that sufficient amounts of 10-formylTHF are available to meet cellular needs. The activity of THF reductase and 10-formyltetrahydrofolate dehydrogenase is regulated by a variety of factors, including the availability of folate and the cellular energy status.
Dysregulation of the 10-formylTHF biosynthetic pathway can lead to various metabolic disorders. For example, deficiencies in folate can impair the synthesis of 10-formylTHF, leading to megaloblastic anemia and other health problems. Additionally, mutations in genes encoding enzymes involved in the 10-formylTHF biosynthetic pathway can also lead to metabolic disorders.
In summary, the 10-formylTHF biosynthetic process is a critical metabolic pathway that produces a crucial cofactor required for purine biosynthesis, DNA replication, and amino acid metabolism. Its regulation is essential for maintaining cellular health and preventing metabolic disorders.
'"
| Protein | Definition | Taxonomy |
|---|---|---|
| Dihydrofolate reductase | A dihydrofolate reductase folA that is encoded in the genome of Escherichia coli K-12. [PRO:DNx, UniProtKB:P0ABQ4] | Escherichia coli K-12 |
| Dihydrofolate synthase/folylpolyglutamate synthase | A dihydrofolate synthase/folylpolyglutamate synthase that is encoded in the genome of Escherichia coli K-12. [PRO:DNx, UniProtKB:P08192] | Escherichia coli K-12 |
| C-1-tetrahydrofolate synthase, cytoplasmic | A C-1-tetrahydrofolate synthase, cytoplasmic that is encoded in the genome of human. [PRO:DNx, UniProtKB:P11586] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| lamotrigine | 1,2,4-triazines; dichlorobenzene; primary arylamine | anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic | |
| methazolamide | Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | sulfonamide; thiadiazoles | |
| pyrimethamine | Maloprim: contains above 2 cpds | aminopyrimidine; monochlorobenzenes | antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
| imatinib | aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines | antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor | |
| trimethoprim | trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge. Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported. | aminopyrimidine; methoxybenzenes | antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic |
| trimetrexate | Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | ||
| cycloguanil | cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil. cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source | triazines | antifolate; antiinfective agent; antimalarial; antiparasitic agent; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
| 4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine | 4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine: structure in first source | ||
| diaveridine | diaveridine : An aminopyrimidine in which the pyrimidine ring carries amino substituents at C-2 and C-4 and a 3,4-dimethoxybenzyl group at C-5. A folic acid antagonist, it is used as a synergist with sulfonamides against the parasitic Eimeria species. diaveridine: RN given refers to parent cpd; structure | aminopyrimidine | antiparasitic agent; drug allergen |
| piritrexim | piritrexim: RN given refers to parent cpd; structure given in first source | ||
| 2,4-diaminoquinazoline | |||
| tetroxoprim | tetroxoprim: structure given in Negwer 5th ed, #6419 | dimethoxybenzene | |
| brodimoprim | brodimoprim : An aminopyrimidine that is 2,4-diaminopyrimidine in which the hydrogen at position 5 has been replaced by a 4-bromo-3,5-dimethoxybenzyl group. brodimoprim: inhibits dihydrofolate reductase | aminopyrimidine; bromobenzenes; methoxybenzenes | antibacterial drug; antiinfective agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
| epiroprim | epiroprim: an analog of trimethoprim with improved antimicrobial and pharmacokinetic properties; structure given in first source | ||
| methylbenzoprim | methylbenzoprim: structure given in first source | ||
| 2,4-diamino-5-benzylpyrimidine | 2,4-diamino-5-benzylpyrimidine: structure given in first source | ||
| 2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine | 2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine: RN given refers to parent cpd; structure given in first source | ||
| methotrexate | dicarboxylic acid; monocarboxylic acid amide; pteridines | abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent | |
| aminopterin | Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic. | dicarboxylic acid | EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen |
| iclaprim | 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine : An aminopyrimidine that is 5-methylpyrimidine-2,4-diamine in which one of the hydrogens of the methyl group has been replaced by a 2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl group. iclaprim : A racemate consisting of equimolar amounts of (R)- and (S)-iclaprim. Both enantiomers exhibit similar, potent bactericidal activity against major Gram-positive pathogens, notably methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA, respectively). iclaprim: has antiviral activity | aminopyrimidine; chromenes; cyclopropanes | |
| n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide | indisulam : A chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group at position 7. It is a carbonic anhydrase inhibitor and a potential anti-cancer agent currently in clinical development. N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide: structure in first source | chloroindole; organochlorine compound; sulfonamide | antineoplastic agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor |
| pd 173955 | PD 173955: inhibits src family-selective tyrosine kinase; structure in first source | aryl sulfide; dichlorobenzene; methyl sulfide; pyridopyrimidine | tyrosine kinase inhibitor |
| dihydrofolate | dihydrofolic acid : A folic acid derivative acted upon by dihydrofolate reductase to produce tetrahydrofolic acid. It interacts with bacteria during cell division and is targeted by various drugs to prevent nucleic acid synthesis. | dihydrofolic acids | Escherichia coli metabolite; mouse metabolite |
| folic acid | folcysteine: used to promote fertility in chickens vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin. | folic acids; N-acyl-amino acid | human metabolite; mouse metabolite; nutrient |
| raltitrexed | N-acyl-amino acid | ||
| n-(4(n-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-l-glutamic acid | |||
| 1843u89 | 1843U89: structure given in first source; a folate analog | ||
| pemetrexed | pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). | N-acyl-L-glutamic acid; pyrrolopyrimidine | antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor |
| 5-methyltetrahydrohomofolic acid | 5-methyltetrahydrohomofolic acid: RN given refers to parent cpd | ||
| cb 3717 | N-acyl-L-glutamic acid | ||
| 5,6,7,8-tetrahydrofolic acid | tetrahydrofolate : A folate obtained by deprotonation of any tetrahydrofolic acid. tetrahydrofolic acid : A group of heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with one or more L-glutamic acid units. | tetrahydrofolic acid | Saccharomyces cerevisiae metabolite |